Tag: HR+/HER2-
-
Assessing Thrombotic Risk in HR+/HER2- Breast Cancer Recurrence
Overview Breast cancer remains the most commonly diagnosed cancer worldwide, with the estrogen receptor–positive, HER2-negative (HR+/HER2−) subtype accounting for a large portion of cases. When breast cancer recurs, patients may face an elevated risk of thromboembolic events (TEEs), including deep vein thrombosis and pulmonary embolism. Understanding and assessing this thrombotic risk is crucial for guiding…
-
Assessing Thrombotic Risk in HR+/HER2- Breast Cancer: A Practical Guide for Clinicians
Overview: Why Thrombotic Risk Matters in HR+/HER2- Breast Cancer Venous thromboembolism (VTE) is a well-recognized complication in cancer patients, including those with hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. While targeted endocrine therapies and CDK4/6 inhibitors have improved outcomes, they may also influence thrombosis risk through complex interactions with tumor biology, treatment regimens, and…